Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer

Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer

No === The quinone based bioreductive drug apaziquone (EO9) failed to demonstrate efficacy in previous phase II studies following intravenous administration. We determined the dose of apaziquone that can be safely administered intravesically and explored its activity for superficial bladder transiti...

Full description

Bibliographic Details
Main Authors: Puri, Rajiv, Palit, V., Loadman, Paul M., Flannigan, G. Michael, Shah, T.K., Choudry, G.A., Basu, Saurajyoti, Double, John A., Lenaz, G., Chawla, S., Beer, M., Kalken, C.V., de Boer, R., Beijnen, J.H., Twelves, Christopher J., Phillips, Roger M.
Language:en
Published: 2009
Subjects:
EO9
Bladder
Carcinoma
Bladder Neoplasms
Transitional Cell
Online Access:http://hdl.handle.net/10454/4150

Internet

http://hdl.handle.net/10454/4150

Similar Items